Figure 6.
Effect of whole or F(ab’)2 anti-CD16 on hPR1A3-mediated lysis. Fluorescence-based ADCC assays were done using human PBMCs as effector cells in a ratio of 100 : 1 with MKN45 target cells. Columns represent mean % lysis from triplicate wells containing both target and effector cells ±10 μg ml−1 hPR1A3 ±second antibody as indicated. The anti-CD16 constructs and anti-PSMA control were added at the same time as the effector cells without prior incubation.